Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Online ahead of print]

Oral Supplementation With omega-3 Fatty Acids and Inflammation Markers in Patients With Chronic Kidney Disease in Hemodialysis

Affiliations

Oral Supplementation With omega-3 Fatty Acids and Inflammation Markers in Patients With Chronic Kidney Disease in Hemodialysis

José Antonio Valle Flores et al. Appl Physiol Nutr Metab.

Abstract

Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death due to cardiovascular complications by 2-3 times compared to the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to one of two groups: the study group (group A; 46 patients) received four capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received four capsules of paraffin oil. The patients' general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin-6, interleukin-10 and tumour necrosis factor alpha) were evaluated. No differences were found between the general characteristics of the patients (P <0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P <0.05). Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P <0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention (P <0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis. Novelty bullets: ●Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. ●This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.

Similar articles

See all similar articles

LinkOut - more resources

Feedback